Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Renal FailureOpen Access

Refining tacrolimus dosing through CYP3A5 pharmacogenetics in Taiwanese renal transplant recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYen-Lin ChangTHTzu-Hung HsiaoYCYi‐Ming Chen

Discussion

Loading...

Member takes

Overview

This retrospective cohort study shows genotype impacts on tacrolimus dosing in renal transplant recipients, suggesting improved safety through pharmacogenetic testing.

Key Points

  • Genotype-guided dosing reduced the likelihood of tacrolimus overexposure by 69%, enhancing patient safety.
  • CYP3A5 *3/*3 carriers required significant dose reductions and had a high rate of overexposure events at 34.14%.
  • The study analyzed pharmacokinetics of tacrolimus in 431 Taiwanese renal transplant recipients post-surgery.
  • Preemptive pharmacogenetic testing could potentially personalize and improve dosing strategies in kidney transplant care.

Cite This Study

Chang et al. (2025) studied this question.

synapsesocial.com/papers/68d41da8713b0b5dfea66e1fhttps://doi.org/10.1080/0886022x.2025.2523567
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipients2025
  2. 2Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review2025
  3. 3Establishing a <i>CYP3A5</i> genotype–guided tacrolimus dosing protocol in adult kidney transplant recipients2025
  4. 4Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Pharmacokinetics and Renal Allograft Rejection in Kidney Transplant Recipients: A Meta-Analysis Across Ethnic Populations2025
  5. 5Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication2025